TRENDING TOPICS
3286 articles found for "investing"
The U.S. dollar tumbles to its lowest level since February 2022 as investors question Fed independence, price in dovish policy shifts, and contemplate potential currency intervention.
Copper prices surge to a historic $13,310 per tonne as Section 232 tariffs drive unprecedented U.S. stockpiling, reshaping global commodity flows and raising questions about supply sustainability.
Vanguard recommends shifting from traditional 60/40 to 40/60 portfolio allocation, expecting only 4.5% annual equity returns over the next decade versus 15% historical average.
Bitcoin trades flat at $88,000 as investors rotate into precious metals, with gold above $5,100 and silver at record highs. Hash Ribbon indicator suggests potential recovery ahead.
Boeing reports Q4 revenue of $23.95 billion, beating estimates by 7%, with 600 aircraft deliveries marking the highest total since 2018. CEO Ortberg says company has 'a lot to be optimistic about.'
The Russell 2000 declined 0.36% Monday even as major indexes extended their winning streak, revealing a growing divergence between large-cap strength and small-cap struggle.
The private credit industry has grown tenfold since 2007, with retail investors now commanding a third of the $1 trillion direct lending market through new semi-liquid vehicles.
Analysts project the S&P 500 will post 15% earnings growth in 2026, with technology contributing 60% of the gains as the market shifts from multiple expansion to fundamental growth.
Gold extends its record-breaking rally above $5,100 per ounce as geopolitical uncertainty and central bank buying fuel unprecedented demand for the precious metal.
Markets climb Monday as investors position ahead of the Federal Reserve decision, earnings from four Magnificent Seven companies, and potential government shutdown.
Zoom shares surge 11% as analysts highlight the video conferencing company's early investment in AI leader Anthropic, now valued at $350 billion.
Pfizer prevails in bidding war for weight-loss drug developer Metsera, paying $10 billion to break into the explosive GLP-1 market dominated by Eli Lilly and Novo Nordisk.